Vela Diagnostics has launched the PathoKey MP UTI ID and AMR PCR test for research use only. This multiplex PCR-based test enables the simultaneous in vitro detection and differentiation of 14 pathogens that cause urinary tract infections, as well as 14 antimicrobial resistance genes encoding resistance to five antibiotics. The test is compatible with common real-time PCR platforms such as the Qiagen Rotor-Gene Q 5/6 plex platforms and Thermo Fisher Scientific QuantStudio 5 real-time PCR system. Vela said that its proprietary Sentosa SA201 Reporter can generate a report that consolidates pathogen and AMR results for each sample when used with the Sentosa SA201 or Applied Biosystems 7500 Fast Dx platform.
The test can be implemented in an automated or manual workflow, Vela noted. Higher-throughput laboratories can choose from two of Vela's automated solutions, which incorporate the Sentosa SX101 instrument for extraction and PCR setup, generating a report within four hours with as little as 30 minutes of hands-on time. The second automated workflow includes the Thermo Fisher KingFisher Flex instrument for even higher throughput, Vela said.
Tethis, a Milan, Italy-based liquid biopsy technology firm, has launched See.d, a universal blood sample prep platform for liquid biopsy. The research-use-only platform performs completely automated and standardized preparation of a blood sample at the point of collection. The platform processes fresh blood collected in EDTA tubes, and automates separation of plasma from cellular fraction, red blood cell lysis and removal, white blood cell dispensation and fixation on SBS slides, and plasma recovery in tubes. At the end of the process, the SBS slides with a fixed monolayer of all white blood cells is made available, and the relative plasma aliquot is provided in a separate tube, Tethis said. The SBS slides are compatible with all analytical pathology techniques, including cytology, immunocytochemistry, immunofluorescence, and fluorescence in situ hybridization for morphological and biomarker-based analysis, the company added. In addition, the plasma is stable for several days and ready for cell-free DNA extraction without any further centrifugation steps, the company said.
Tethis is currently validating the platform for CE-IVD marking, developing liquid biopsy tests, and seeking partnerships with diagnostic and drug-development companies, it said.
Invitae has expanded its Pharmacogenomics Panel to include genes associated with differential response to mental health drugs. While the PGx panel analyzes drug response-associated variants in 38 genes, the mental health-specific panel aligns with some payor coverage that limits the number of genes covered in this setting, according to the firm. The test's treatment guidance is based on the latest PGx guidelines and published evidence, Invitae added. In addition to helping personalize mental health treatment, the company's testing service also guides therapeutic strategies for patients in the areas of high-risk primary care, cardiology, endocrinology, pain management, and oncology. As part of the expanded testing service, physicians will also have access to Invitae's YouScript clinical decision support tool.
Meridian Bioscience has launched two new master mixes for isothermal amplification, the Lyo-Ready Direct DNA LAMP Saliva Mix and Lyo-Ready Direct RNA/DNA LAMP Saliva Mix. The mixes are designed specifically for saliva and sputum samples and are compatible with lyophilization, which can help with creating ambient-temperature stable molecular diagnostic assays. The mixes are also designed for extraction-free amplification.
Single-cell analysis firm KromaTiD has launched its KromaTiD Pinpoint FISH probes. They are designed to detect biomarkers and to quantify chromosomal rearrangements, structural variants, and mutations in targets of interest. Pinpoint FISH probes targeting sub-telomeres and centromeres can be labeled with any of five fluor probe color options. KromaTiD also offers custom probes and labeling.
Promega has launched the Spectrum CE System, a capillary electrophoresis instrument designed for the forensics community. The platform holds four 96-well plates that are continuously accessible while the instrument is running. It is compatible with 5-, 6-, and 8-color STR kits and can be used with kits from several vendors. Promega also said it plans to release an 8-color PowerPlex System later this year.
PerkinElmer has launched its ultrarapid whole-genome sequencing service, which provides physicians with results in five days to help them manage and improve outcomes for patients in neonatal and pediatric intensive care units. The service, being offered through PerkinElmer Genomics, uses a dried blood sample for phenotype-driven analysis with a mean coverage of 40x of a patient’s genome, the Waltham, Massachusetts-based company said. It includes a StepOne Comprehensive Biochemical Profile, which screens for more than 70 inherited conditions and disorders including the recommended universal newborn screening panel. The service also provides analysis of the mitochondrial genome; CNV detection to identify deletions, duplications, and other gene- and chromosomal-level events; and a spinal muscular atrophy and repeat disorders screen.
Neogen and Gencove have launched InfiniSeek, a cattle whole-genome sequencing and genotyping solution. The assay simultaneously yields low-pass whole-genome sequencing and high-coverage genotyping at preselected loci in a single molecular reaction, providing information on genomic sequence, specific genetic traits, and parentage markers. It has been validated to show more than 99 percent concordance with deep WGS. Pricing was not disclosed.
Thermo Fisher Scientific has launched a 384-well option for its Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System. The company originally launched the instrument in the US last November with a 96-well block. With the new option, users can easily switch between 96-well and 384-well blocks in order to change the throughput of their assays as needed.
Mawi DNA Technologies has launched NextSwab, a plastic swab for high-efficiency nasal sample collection. The company released this product in response to the COVID-19 swab shortage. The swab head has two channels, separated by a septum, that retain the collected nasal material. This can then be released into transport medium with a gentle shake. The swab is compatible with many sample transport tubes and does not require any preparation for specimen collection. It fully releases its contents into the sample transport medium.